![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/28/2905748/0/en/ARS-Pharmaceuticals-Announces-EURneffy-adrenaline-nasal-spray-Recommended-for-Approval-by-CHMP-for-Emergency-Treatment-of-Allergic-Reactions-anaphylaxis.html
https://www.globenewswire.com/news-release/2024/05/09/2879194/0/en/ARS-Pharmaceuticals-Highlights-neffy-Regulatory-Progress-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/30/2872354/0/en/ARS-Pharmaceuticals-Submits-Response-for-neffy-epinephrine-nasal-spray-Marketing-Authorization-Application-to-EMA-s-CHMP-and-Enters-License-Agreement-with-CSL-Seqirus-for-Commercia.html
https://www.globenewswire.com/news-release/2024/04/03/2857016/0/en/ARS-Pharmaceuticals-Submits-Response-to-FDA-Complete-Response-Letter-for-neffy-Epinephrine-Nasal-Spray.html
https://www.pharmaceutical-technology.com/news/ars-gears-up-for-neffy-us-approval/
https://www.globenewswire.com/news-release/2024/03/21/2850618/0/en/ARS-Pharmaceuticals-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/07/2842745/0/en/ARS-Pharmaceuticals-Reviews-Recent-Clinical-Updates-and-Commercial-Opportunity-at-neffy-Investor-Day.html
https://www.globenewswire.com//news-release/2024/03/06/2841498/0/en/ARS-Pharmaceuticals-to-Participate-in-the-Leerink-Partners-Global-Biopharma-Conference-2024.html
https://www.globenewswire.com//news-release/2024/02/26/2835180/0/en/ARS-Pharmaceuticals-announces-neffy-meets-primary-endpoints-and-shows-rapid-symptom-control-in-Phase-2-urticaria-clinical-study.html
https://www.globenewswire.com//news-release/2024/02/22/2833758/0/en/ARS-Pharmaceuticals-to-Host-Virtual-neffy-Investor-Day-on-March-7-2024.html